Pfizer Reports Results of Abrocitinib in P-III JADE DARE Study to Treat Atopic Dermatitis

August 30, 2021 Auto Bot Atopic Dermatitis, Clinical Trials, P-III, Pfizer 0

Shots:

  • The head-to-head P-III JADE DARE study involves assessing the efficacy of Abrocitinib (200mg, qd, PO) vs dupilumab (300mg, SC, q2w followed by 600mg induction dose) in adult patients on background topical therapy with moderate to severe AD
  • The study met its co-1EPs of at least a 4-point improvement in the severity of PP-NRS4 @2wks. and the proportion of patients achieving EASI-90 @4wks. The study also met its 2EPs i.e proportion of patients achieving EASI-90 @16wks.
  • In general, abrocitinib was superior to dupilumab in each evaluated efficacy measure and had a safety profile consistent with previous studies

Click here to­ read full press release/ article | Ref: Pfizer | Image: Wall Street Journal

The post Pfizer Reports Results of Abrocitinib in P-III JADE DARE Study to Treat Atopic Dermatitis first appeared on PharmaShots.